Avivagen Inc (V:VIV) is advancing feed additives based on its OxC-beta (fully oxidized beta-carotene) technology, which improves immune function and promote growth. The recent approval in New Zealand should build upon commercial sales already secured in parts of Asia.
OxC-beta Livestock intended for global feed markets
OxC-beta Livestock aims to reduce the use of antibiotic growth promoters (AGP) in feed. It has been studied in over 25 trials, with data showing that it can lead to significant weight gain improvements in broiler poultry and swine and protect against certain gastrointestinal afflictions. The use of AGPs in the feedstock of cattle, swine and poultry has been banned since 2006 in Europe. Restrictions began in the US in 2017 as their use has become a source of concern to health authorities and consumers alike. The removal of antibiotics from feeds can reduce the promotion of antibiotic resistant pathogens that can affect human health.
Sales opportunities in feed and other markets
Following approvals in Asia, industrial-scale sales began in FY17, with lead customer, UNAHCO of the Philippines, purchasing 800 kg of OxC-beta Livestock 10% premix, which can supplement c 45,000 tons of commercial feed. Avivagen estimates the global animal feed market for which OxC-beta can be used (in targeted species of poultry, swine and cattle) exceeds 900m tons. It estimates that 10% market penetration in global feed markets can provide up to US$120m gross profit per year, although it must also compete with other non-antibiotic additives. Avivagen also markets OxC-beta supplements for the companion animal market.
To read the entire report Please click on the pdf File Below: